FOR MORE THAN 90% OF RARE DISEASES, NO TREATMENT EXISTS TO DATE, EITHER TO CURE OR ONLY TO IMPROVE THE LIVING CONDITIONS OF AFFECTED PATIENTS.
"In 2014, after years of research, we created ProGeLife, a start-up entirely dedicated to the research and development of new treatments for rare genetic diseases in children with accelerated aging. These treatments can also be used to prevent or slow down the appearance of diseases that may occur during physiological aging.
Our priority is to improve patient future."
Professors Nicolas Lévy and Pierre Cau,
Aix-Marseille University, founders of ProGeLife
- To discover, patent and develop treatments to fight against rare genetic diseases characterized by accelerated or premature aging in children, ProgeriaProgeria : This paradigmatic disease of aging is also known as Hutchinson-Gilford syndrome. Extremely rare genetic disease (aroung 300 living patients worldwide) characterized by an accelerated and premature aging due to the abnormal accumulation of progerin., Xeroderma pigmentosumXeroderma pigmentosum : A group of rare genetic diseases characterized by a defect in one of the DNA repair pathways. Depending on the mutated protein, eight XP diseases are known, XPA to XPG and XPV.
- Further apply these treatments to more frequent age-related diseases within general population.
through controling and modifying the disease course
ProGeLife research and development are focussed on two rare genetic diseases affecting childrens and worsening the quality of life of patients and their family : ProgeriaProgeria : This paradigmatic disease of aging is also known as Hutchinson-Gilford syndrome. Extremely rare genetic disease (aroung 300 living patients worldwide) characterized by an accelerated and premature aging due to the abnormal accumulation of progerin. and Xeroderma pigmentosumXeroderma pigmentosum : A group of rare genetic diseases characterized by a defect in one of the DNA repair pathways. Depending on the mutated protein, eight XP diseases are known, XPA to XPG and XPV..
- Progeria : the paradigmatic disease of accelerated and premature aging, whose the responsible mutation was discovered by the two scientists funders of ProGeLife.
- Xeroderma pigmentosum : the «Children of the Moon» disease.
An excellent R&D team,
skilled in pathological
or physiological aging.
ProGeLife is developing drug candidates
for Progeria and Xeroderma pigmentosum,
the "Children of the Moon" disease.
In 2003, Nicolas Lévy, Professor in Medical Genetics and Pierre Cau, Professor in Cell Biology, both researchers and Hospital Practitioners in La Timone Hospital in Marseille, discovered the mutation responsible for Progeria, a exceedingly rare disease, characterized by an accelerated and premature aging. A world premiere !
Over the years, the research team designed a first drug combination devoted to the treatment of Progeria and that could be expanded to physiological aging, whose Progeria represents the best model.
A patent has been filed in 2006 and the first european clinical trial for Progeria took place in Marseille from 2008 to 2013 with encouraging results : the drug combination slows down the disease course and reduces some clinical and biological symptoms of the disease.
ProGeLife is entirely devoted to the development of molecules exhibiting an high therapeutic potential for children rare diseases characterized by accelerated and premature aging. ProGeLife aspiration : to improve the life of patient and their familty !
A new patent has been filed in 2015 describing a new family of promising molecules devoted to the cure of Progeria. In 2017, the proofs of efficacy have been published in the famous international journal EMBO Molecular Medicine.
Our management team
- 35 years of experience in business creation including 16 years in innovation
- 20 years of experience in research valuation and investment (Protisvalor Méditerranée, Pertinence Invest)
- Polytechnique School (X94), Master 2 «Physiology of extreme conditions» (2015)
- Former experience (17 years) in financing and investment bank
- Showed recently (2015) the positive effects of diving on post-traumatic stress
Chief Medical Officer (CMO)
- Professor in Medical genetics (MD, PhD), Hospital Practitioner Hospitalier, Marseille
- Chief of Medical genetics Department, La Timone Hospital, Marseille
- Director of research unit Aix Marseille Université / INSERM UMR_S 1251 "Marseille Medical Genetics"
- Funder and first director of the Fundation for rare diseases
- Funder and project leader of institute GIPTIS « Genetics Institute for Patients Therapies Innovation & Science » for rare diseases.
Chief Scientific Officer (CSO),
- Professor in Cell Biology (MD, PhD), emeritus, former Hospital Practioner Hospitalier, Marseille
- Former Chief of Cell Biology Lab, La Timone Hospital, Marseille (1999-2013)
HEAD OF CLINICAL DEVELOPMENT, PhD
- PhD, graduated by Centre d’Enseignement de la Statistique à la Santé Publique, à la Médecine et à la Biologie (CESAM), Sorbonne University, Paris
- Skilled in Biotech world (Trophos) : therapeutic development, clinical research, regulatory affairs.